An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Coverage of obesity drugs in health plans and the rapid adoption of artificial intelligence are two areas of change that health plans will face during the coming year. A panel of Avalere experts ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will summarize the bulls’ thesis on NVO.

The FDA on Tuesday approves Ozempic, the weight loss drug made by Novo Nordisk, for the treatment of chronic kidney disease ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

While the Dutch company expects to report profits up between 4% and 8% when it releases its full-year 2024 financial results on 12 February 2025, the brewer faces some significant headwinds ...

Concern is growing among Democrats after President Donald Trump reversed some of the former president’s executive orders, ...

The new year means a new administration and new price negotiations for some medications. Ozempic and Wegovy have been added to Medicare's list of drugs whose prices will be negotiated between drug ...